What is HC Wainwright’s Forecast for argenx FY2024 Earnings?

argenx SE (NASDAQ:ARGX) – Stock analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for argenx in a research note issued to investors on Tuesday, January 14th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $2.30 per share for the year, up from their prior estimate of $0.78. HC Wainwright currently has a “Buy” rating and a $717.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is $2.17 per share. HC Wainwright also issued estimates for argenx’s Q4 2024 earnings at $1.49 EPS, Q1 2025 earnings at $1.23 EPS, Q2 2025 earnings at $1.69 EPS, Q3 2025 earnings at $1.65 EPS, Q4 2025 earnings at $1.80 EPS, FY2025 earnings at $6.36 EPS, FY2026 earnings at $18.58 EPS, FY2027 earnings at $31.03 EPS, FY2028 earnings at $43.49 EPS and FY2029 earnings at $58.70 EPS.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the prior year, the business posted ($1.25) earnings per share.

ARGX has been the topic of several other research reports. Wedbush reaffirmed an “outperform” rating and issued a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Oppenheimer restated an “outperform” rating and issued a $675.00 target price (up from $646.00) on shares of argenx in a research note on Thursday, November 21st. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Truist Financial reissued a “buy” rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a research report on Tuesday. Finally, Wells Fargo & Company upped their target price on argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Trading Down 0.8 %

Shares of ARGX opened at $659.81 on Friday. The company has a market cap of $39.83 billion, a P/E ratio of -749.78 and a beta of 0.59. argenx has a twelve month low of $349.86 and a twelve month high of $678.21. The company’s fifty day simple moving average is $619.30 and its 200-day simple moving average is $554.23.

Institutional Investors Weigh In On argenx

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. Cromwell Holdings LLC raised its position in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC raised its position in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after buying an additional 56 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in argenx in the 2nd quarter valued at about $76,000. Fulton Bank N.A. purchased a new position in argenx in the 4th quarter worth approximately $226,000. Finally, Blue Trust Inc. increased its holdings in shares of argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.